Personalizing KRAS-mutant allele–speciﬁc therapies

Chiara Falcomatà; Günter Schneider; Dieter Saur

doi:10.1158/2159-8290.CD-19-1261

Personalizing KRAS-mutant allele–speciﬁc therapies

Chiara Falcomatà
, Günter Schneider
, Dieter Saur

Lehrstuhl für Urologie

Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung

7 Zitate (Scopus)

Abstract

KRAS^G12R mutations occur almost exclusively in pancreatic ductal adenocarcinoma. The results of a study that reveals specific differences in KRAS downstream signaling and metabolic rewiring of pancreatic cancer cells harboring KRAS^G12R mutations promise to improve our possibilities to better stratify patients for individualized therapies.

Originalsprache	Englisch
Seiten (von - bis)	23-25
Seitenumfang	3
Fachzeitschrift	Cancer Discovery
Jahrgang	10
Ausgabenummer	1
DOIs	https://doi.org/10.1158/2159-8290.CD-19-1261
Publikationsstatus	Veröffentlicht - Jan. 2020

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gute Gesundheit und Wohlergehen

Zugriff auf Dokument

10.1158/2159-8290.CD-19-1261

Andere Dateien und Links

Verknüpfung zur Publikation in Scopus

Dieses zitieren

@article{90b25d284a4d4e609326245a2b7688d5,

title = "Personalizing KRAS-mutant allele–speciﬁc therapies",

abstract = "KRASG12R mutations occur almost exclusively in pancreatic ductal adenocarcinoma. The results of a study that reveals specific differences in KRAS downstream signaling and metabolic rewiring of pancreatic cancer cells harboring KRASG12R mutations promise to improve our possibilities to better stratify patients for individualized therapies.",

author = "Chiara Falcomat{\`a} and G{\"u}nter Schneider and Dieter Saur",

note = "Publisher Copyright: {\textcopyright} 2020 American Association for Cancer Research.",

year = "2020",

month = jan,

doi = "10.1158/2159-8290.CD-19-1261",

language = "English",

volume = "10",

pages = "23--25",

journal = "Cancer Discovery",

issn = "2159-8274",

publisher = "American Association for Cancer Research Inc.",

number = "1",

}

TY - JOUR

T1 - Personalizing KRAS-mutant allele–speciﬁc therapies

AU - Falcomatà, Chiara

AU - Schneider, Günter

AU - Saur, Dieter

PY - 2020/1

Y1 - 2020/1

N2 - KRASG12R mutations occur almost exclusively in pancreatic ductal adenocarcinoma. The results of a study that reveals specific differences in KRAS downstream signaling and metabolic rewiring of pancreatic cancer cells harboring KRASG12R mutations promise to improve our possibilities to better stratify patients for individualized therapies.

AB - KRASG12R mutations occur almost exclusively in pancreatic ductal adenocarcinoma. The results of a study that reveals specific differences in KRAS downstream signaling and metabolic rewiring of pancreatic cancer cells harboring KRASG12R mutations promise to improve our possibilities to better stratify patients for individualized therapies.

UR - https://www.scopus.com/pages/publications/85077674285

U2 - 10.1158/2159-8290.CD-19-1261

DO - 10.1158/2159-8290.CD-19-1261

M3 - Article

C2 - 31919121

AN - SCOPUS:85077674285

SN - 2159-8274

VL - 10

SP - 23

EP - 25

JO - Cancer Discovery

JF - Cancer Discovery

IS - 1

ER -

Personalizing KRAS-mutant allele–speciﬁc therapies

Abstract

UN SDGs

Zugriff auf Dokument

Andere Dateien und Links

Fingerprint

Dieses zitieren